Our study using ACT-1004-1239, a CXCR7 antagonist of the β-arrestin pathway, provides evidence that the observed efficacy obtained with CCX771 in ALI was likely due to its functional antagonistic effect and not to its agonistic effect. This evidence concerns the gene ACKR3 and acute respiratory distress syndrome.